NCT04575415 2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown
Clinical Trials
3 trialsNCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
NCT02140333 2015-02-12
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Unknown